A final appraisal document has been published indicating the subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, meaning that eligible patients can now receive the innovative treatment.
Patients will, however, only receive the drug if they are eligible for preventive C1-esterase inhibitor (C1-INH) treatment in line with NHS England’s commissioning policy and the lowest dosing frequency of Takhzyro is used in line with the summary of product characteristics…
